Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children

J
John Christenson, MD

Primary Investigator

Administratively Closed
100 years or below
All
Phase N/A
1 participants needed
1 Location

Brief description of study

The purpose of this expanded access IND (compassionate use) program is to provide stockpiled tecovirimat for treatment of non-variola orthopoxvirus infections and secondary treatment of complications from replication-competent vaccinia vaccine in adults and children.
 

Detailed description of study

All patient populations, who meet eligibility criteria, can receive tecovirimat treatment under this IND program (e.g., children and all adults including pregnant and nursing individuals, and prisoners). Clinical considerations of tecovirimat therapy during an outbreak may evolve depending on the duration and nature of the outbreak and event-based information that may become available during the outbreak
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: orthoproxvirus, Riley
  • Age: 100 years or below
  • Gender: All

Inclusion Criteria:
  •  
Exclusion Criteria:
  •  
  • Known allergy to tecovirimat and/or inactive ingredients in tecovirimat
  • For IV tecovirimat only: patients with severe renal impairment (creatinine clearance <30 mL/min). Oral tecovirimat is an option for patients with severe renal impairment.
 

Updated on 28 Apr 2025. Study ID: PINF-CDC-TPOXX-EAP, 16103

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team